A John Ashcroft
Overview
Explore the profile of A John Ashcroft including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
683
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cook G, Ashcroft A, Senior E, Olivier C, Hockaday A, Richards J, et al.
Lancet Haematol
. 2024 Sep;
11(11):e816-e829.
PMID: 39250926
Background: The efficacy of consolidation and maintenance in the context of salvage autologous haematopoietic stem-cell transplantation (HSCT) for relapsed multiple myeloma remains unclear. We aimed to assess whether consolidation after...
2.
De Tute R, Cook G, Cairns D, Brown J, Cavenagh J, Ashcroft A, et al.
Bone Marrow Transplant
. 2024 Jan;
59(3):431-434.
PMID: 38195983
No abstract available.
3.
Carmichael J, Seymour F, McIlroy G, Tayabali S, Amerikanou R, Feyler S, et al.
Blood Cancer J
. 2023 Mar;
13(1):38.
PMID: 36922489
The COVID-19 pandemic has had global healthcare impacts, including high mortality from SARS-CoV-2 infection in cancer patients; individuals with multiple myeloma (MM) are especially susceptible to poor outcomes. However, even...
4.
Snowden J, Ahmedzai S, Cox A, Cairns D, Ashcroft A, Williams C, et al.
Bone Marrow Transplant
. 2022 Jun;
57(10):1507-1513.
PMID: 35768571
The Myeloma X trial provided a platform to explore genetics in relation to systematic assessment of patient-reported outcomes at key points during salvage treatment in multiple myeloma (MM) patients. Blood...
5.
Cook G, Ashcroft A, Pratt G, Popat R, Ramasamy K, Kaiser M, et al.
Br J Haematol
. 2020 May;
190(2):e83-e86.
PMID: 32438482
No abstract available.
6.
Cook G, Royle K, OConnor S, Cairns D, Ashcroft A, Williams C, et al.
Br J Haematol
. 2019 Feb;
185(3):450-467.
PMID: 30729512
The Myeloma X trial (ISCRTN60123120) registered patients with relapsed multiple myeloma. Participants were randomised between salvage autologous stem cell transplantation (ASCT) or weekly cyclophosphamide following re-induction therapy. Cytogenetic analysis performed...
7.
Striha A, Ashcroft A, Hockaday A, Cairns D, Boardman K, Jacques G, et al.
Trials
. 2018 Mar;
19(1):169.
PMID: 29514706
Background: Multiple myeloma (MM) is a plasma cell tumour with an approximate annual incidence of 4500 in the UK. Therapeutic options for patients with MM have changed in the last...
8.
Cook G, Ashcroft A, Cairns D, Williams C, Brown J, Cavenagh J, et al.
Lancet Haematol
. 2016 Jul;
3(7):e340-51.
PMID: 27374467
Background: The Myeloma X trial previously reported improved durability of response (time to disease progression) in patients with relapsed multiple myeloma with salvage autologous stem-cell transplantation (ASCT) compared with oral...
9.
Cook G, Williams C, Brown J, Cairns D, Cavenagh J, Snowden J, et al.
Lancet Oncol
. 2014 Jun;
15(8):874-85.
PMID: 24948586
Background: Relapsed multiple myeloma has no standard treatment, and the role of autologous stem-cell transplantation (ASCT) has not been fully defined. We aimed to compare high-dose melphalan plus salvage ASCT...
10.
Morgan G, Davies F, Gregory W, Szubert A, Bell S, Drayson M, et al.
Blood
. 2012 Apr;
119(23):5374-83.
PMID: 22498739
The Medical Research Council Myeloma IX Trial (ISRCTNG8454111) examined traditional and thalidomide-based induction and maintenance regimens and IV zoledronic acid (ZOL) and oral clodronate (CLO) in 1960 patients with newly...